Dysregulated NLRP3 inflammasome activation leads to an imbalance between these systems and the release of inflammatory factors that mediate metabolic disorders, such as obesity [46], type 2 diabetes mellitus (T2DM) [47], and atherosclerosis [48], through autocrine or paracrine mechanisms. This evidence concerns the gene NLRP3 and metabolic disease.